Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus
Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus
Not yet recruiting · NCT05504187 · Registry updated 2024-10-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus | Cytopenia, Hemic and Lymphatic Diseases, Skin and Connective Tissue Diseases, autoimmune disease, blood platelet disease, connective tissue disorder, hematologic disorder, immune system disorder, systemic lupus erythematosus, thrombocytopenia, thrombotic microangiopathy | Not yet recruiting | Phase 2 | 2024-10-28 | NCT05504187 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Kira Pharmacenticals (US), LLC. | 3 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||